BRIDGEWATER, N.J., Oct. 9, 2012 /PRNewswire-iReach/ -- Semantelli Corporation announced today that a global, multibillion specialty pharmaceutical company has deployed Semantelli's AETrackerTM to detect and manage adverse events and product complaints generated in company sponsored mobile applications.
AETracker is the healthcare industry's only software solution that detects and manages Adverse Events in company sponsored social media and mobile apps.
"We are really excited about this development in the #mhealth sector. By deploying Semantelli, companies are starting to ensure sponsored mobile applications are compliant from pharmacovigilance perspective. There are thousands of mobile health applications available on smart phones and tablets. The majority of them are not even in the sponsor's pharmacovigilance radar. We feel all of these applications require monitoring on an ongoing basis." said Siva Nadarajah, CEO of Semantelli Corp.
There are close to 13,000 health apps available for consumers on iTunes and Google Play. Only 100 of them are approved by FDA. According to Microsoft founder Bill Gates, mobile devices are expected to provide health care to over 500 million people by 2015, improving immunization programs and offering cheap diagnostic tools to combat many of the world's diseases.
In August of 2011, Semantelli launched AETracker to help pharmaceutical companies monitor and manage adverse events reported on company owned Facebook pages. Due to customer demand, AETracker was later extended to monitor mobile apps and other sponsored social outlets. Since the launch, AETracker has been deployed by some of the top 10 pharmaceutical and healthcare companies.
Powered by patent pending technology and 24x7 pharmacovigilance support, AETracker helps pharmaceutical companies monitor and respond to potential adverse events, product complaints and off-label comments on company sponsored social media and mobile applications.
Semantelli is the leader in Semantic based enterprise listening solutions for the global life sciences industry. Companies use Semantelli's compliance sensitive solutions to monitor social media, web, and internal unstructured data sources to find previously unknown early warnings, threats, and opportunities. Semantelli's customers have found immediate ROI, ranging from spotting early compliance warnings, new trends, targeted promotions and engaging doctors who have shown signs of switching to other brands.
Semantelli is a privately-held company headquartered in Bridgewater, NJ.
For more information go to: http://www.semantelli.com/pharma/
Media Contact: John Jason Semantelli Corp., 1-866-277-9057, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Semantelli Corp.